Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients

Surveillance Pharmacologique et Immunitaire précoce après Conversion au Belatacept Chez Les Patients Ayant Subi Une Transplantation rénale : étude Pilote

Single-center, prospective, translational, clinical-biological, multidisciplinary study

All patients starting belatacept will be informed about non-interventional study and will be included unless they do not accept (non-opposition, consent is not required). Patients will be included and followed up during the 6 first months, i.e. 9 infusions. Blood samples (3 heparinized tubes of 7ml + 1 dry tube without separator gel of 5ml, i.e. 26ml maximum per sample) and urine samples will be harvested before each perfusions and in case of rejection. Clinical and biological data will be collected in an electronic CRF.

Inclusion Criteria:

• Age ≥ 18 years
• Renal transplant patient
• Patient converted from an anticalcineurin to belatacept

Exclusion Criteria:

• Opposition to data processing
• Hemoglobin < 9g/dL
• Patient under judicial protection
• Pregnant or breastfeeding woman